Navigation Links
Stem cell study offers hope for Parkinson's patients
Date:8/23/2011

Scientists have for the first time generated stem cells from one of the most rapidly progressing forms of Parkinson's disease.

The development will help research into the condition as it will enable scientists to model the disease in the laboratory to shed light on why certain nerve cells die.

Scientists, funded with a 300,000 grant from the charity Parkinson's UK, took skin samples from a patient diagnosed with one of the most progressive types of Parkinson's.

The research, led by the University of Edinburgh in collaboration with UCL (University College London), then used these skin cells to generate brain nerve cells affected by the disease.

The ability to generate these nerve cells will make it easier to monitor the effectiveness of potential new drugs that could slow or halt progress of the condition.

The aim would be to find drugs that can prevent the death of these key cells known as neurons which break down as a result of Parkinson's.

Dr Tilo Kunath, of the University of Edinburgh's Medical Research Council Centre for Regenerative Medicine, said: "Current drugs for Parkinson's alleviate symptoms of the condition. Modelling the disease in a dish with real Parkinson's neurons enables us to test drugs that may halt or reverse the condition.

"This study provides an ideal platform to gain fresh insight into the condition, and opens a new area of research to discover disease-modifying drugs."

The neuron cells were generated from a patient with a form of Parkinson's that progresses rapidly and can be diagnosed in people in their early 30s.

People with this form of Parkinson's have twice as many of the genes that produce a protein alpha synuclein compared with the general population.

Although this form of Parkinson's is rare the protein involved is linked to virtually all types of the disease.

Dr Michael Devine, of the UCL Institute of Neurology said, "Unders
'/>"/>

Contact: Tara Womersley
tara.womersley@ed.ac.uk
44-131-650-9836
University of Edinburgh
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
2. Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study
3. Microbial study reveals sophisticated sensory response
4. BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
5. New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility
6. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
7. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
8. As New Data Wave Begins, a Gene Study in One Disease Discovers Mutations in an Unrelated Disease
9. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
10. Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds
11. Diesel fumes pose risk to heart as well as lungs, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015 DryLet, LLC ... in applications such as animal waste reduction, bioremediation, ... reduction in wastewater treatment plants and restaurant kitchen ... at the Texas Commission on Environmental Quality (TCEQ) ... Austin, Texas. , The company will highlight three ...
(Date:4/27/2015)...  Together with its customers, Elekta raised EUR 30,575 ... Barcelona . The funds will be donated ... to improve cancer care, specifically radiation oncology care, around ... patient should be denied potentially life-saving treatment simply because ... hospitals and clinics around the world to take care ...
(Date:4/24/2015)... Tempe, AZ (PRWEB) April 24, 2015 ... Arizona State University (ASU) have entered into an agreement ... , A memorandum of agreement signed by the universities ... learning, student success and other services particularly, though not ... , “We have complementary strengths and a similar set ...
(Date:4/24/2015)... , April 24, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics including high value and difficult to ... public offering of 6,000,000 shares of its common stock ... share. Of the shares being offered, 2,610,000 are being ... being offered by existing stockholders. Pfenex will not receive ...
Breaking Biology Technology:DryLet to Showcase Multiple Products at Texas Commission on Environmental Quality Trade Fair and Conference May 5-6 in Austin, Texas 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Pfenex Inc. Announces Pricing Of Follow-on Offering 2
... into the human brain to understand its functions in ... illness — has long been a challenge for researchers. ... and sensors that can damage tissue while only reading ... Jonathan Viventi , assistant professor at ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... it will host an Investor and Analyst Day at NASDAQ ... 2:00 to 5:00 pm ET. Key members of the company,s ... specifically focusing on the recent commercial launch of the MaterniT21 ...
... Calif., Nov. 14, 2011 VIVUS, Inc. (NASDAQ: ... TA-314, a phase 3 long-term safety and efficacy study ... erectile dysfunction (ED), was presented over the weekend at ... Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, ...
Cached Biology Technology:Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 2Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 3Flexible Sensors Offer Unprecedented View of Brain Activity During Epileptic Seizures 4Sequenom to Host Analyst Day on Monday, November 14, 2011 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 215-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 315-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 4
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... When a foreign object such as a catheter enters the ... into a slick coating a biofilm that is ... cannot be defeated by a basic approach of conventional means. ... reveals the key players in the network and how they ...
... 2010 China PharmaHub Corp. (OTC Bulletin Board: ... agreement to be a distributor for Integrated Biometrics ("IB"), ...  PharmaHub will have the exclusive distribution rights in China, ... to sell IB products to customers in the Pharmaceutical, ...
... soldiers in the battlefield healthy, the U.S. Army is exploring ... Current techniques for analyzing water in the field can take ... Lipkens of Western New England College in Springfield, Massachusetts and ... They are working on an alternative technology that uses sound ...
Cached Biology News:Research provides new leads in the case against drug-resistant biofilms 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 2China PharmaHub Signs Distribution Agreement with Integrated Biometrics 3
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
R26.4C...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
Biology Products: